The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus

Trial Profile

The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Dulaglutide (Primary) ; Insulin glargine; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms AWARD-4
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Jun 2017 Results of a pooled post-hoc analysis of AWARD-4 and AWARD-9 studies, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Results of a post-hoc analysis from AWARD -2, -4, and -5 studies evaluating the effect of dulaglutide on A1c in type 2 diabetes patients positive or negative for GAD antibodies, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top